These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34508023)

  • 1. Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors.
    Kably B; Billaud EM; Derobertmasure A; Blanchard A; Boutouyrie P; Azizi M
    J Hypertens; 2022 Feb; 40(2):348-355. PubMed ID: 34508023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure.
    Struthers AD; MacFadyen R; Fraser C; Robson J; Morton JJ; Junot C; Ezan E
    J Am Coll Cardiol; 1999 Dec; 34(7):2072-7. PubMed ID: 10588226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study.
    Azizi M; Ménard J; Peyrard S; Lièvre M; Marre M; Chatellier G
    Diabetes Care; 2006 Jun; 29(6):1331-6. PubMed ID: 16732017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.
    Azizi M; Ezan E; Reny JL; Wdzieczak-Bakala J; Gerineau V; Ménard J
    Hypertension; 1999 Mar; 33(3):879-86. PubMed ID: 10082503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of immunoreactive acetyl-Ser-Asp-Lys-Pro in human plasma and urine by liquid chromatography-electrospray mass spectrometry.
    Junot C; Pruvost A; Créminon C; Grognet JM; Benech H; Ezan E
    J Chromatogr B Biomed Sci Appl; 2001 Mar; 752(1):69-75. PubMed ID: 11254199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats.
    Junot C; Nicolet L; Ezan E; Gonzales MF; Menard J; Azizi M
    J Pharmacol Exp Ther; 1999 Dec; 291(3):982-7. PubMed ID: 10565814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis.
    Junot C; Menard J; Gonzales MF; Michaud A; Corvol P; Ezan E
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1257-61. PubMed ID: 10336514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass spectrometric quantification of AcSDKP-NH2 in human plasma and urine and comparison with an immunoassay.
    Mesmin C; Cholet S; Blanchard A; Chambon Y; Azizi M; Ezan E
    Rapid Commun Mass Spectrom; 2012 Jan; 26(2):163-72. PubMed ID: 22173804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
    Azizi M; Junot C; Ezan E; Ménard J
    Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations.
    Comte L; Lorgeot V; Volkov L; Allegraud A; Aldigier JC; Praloran V
    Eur J Clin Invest; 1997 Sep; 27(9):788-90. PubMed ID: 9352252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production.
    Azizi M; Junot C; Ezan E; Hallouin MC; Guyene T; Ménard J
    J Mol Med (Berl); 2002 Aug; 80(8):492-8. PubMed ID: 12185449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catabolism of the hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro: a new insight into the physiological role of the angiotensin-I-converting enzyme N-active site.
    Rousseau-Plasse A; Lenfant M; Potier P
    Bioorg Med Chem; 1996 Jul; 4(7):1113-9. PubMed ID: 8831983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs.
    Srivastava SP; Goodwin JE; Kanasaki K; Koya D
    Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32085655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a quantitative multiplex LC-MS/MS assay of carvedilol, enalaprilat, and perindoprilat in dried blood spots from heart failure patients and its cross validation with a plasma assay.
    Joubert A; Joubert A; van der Merwe M; Norman J; Castel S; Denti P; Sliwa K; Maartens G; Sinxadi P; Wiesner L
    J Mass Spectrom Adv Clin Lab; 2023 Jan; 27():7-17. PubMed ID: 36568714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.
    Srivastava SP; Goodwin JE; Kanasaki K; Koya D
    Br J Pharmacol; 2020 Aug; 177(16):3691-3711. PubMed ID: 32352559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-effect relationship of perindopril 10, 14 and 20mg assessed by urine and plasma AcSDKP levels in mildly sodium-depleted healthy volunteers.
    Monge M; Paquet V; Bergerot D; Zhygalina V; Blanchard A
    Int J Cardiol; 2016 Nov; 222():648-653. PubMed ID: 27517656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study).
    Gupta P; Voors AA; Patel P; Lane D; Anker SD; Cleland JGF; Dickstein K; Filippatos G; Lang CC; van Veldhuisen DJ; Metra M; Zannad F; Samani NJ; Jones DJL; Squire IB; Ng LL
    Eur J Heart Fail; 2021 Jul; 23(7):1182-1190. PubMed ID: 33759308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an enzyme immunoassay for a stable amidated analog of the hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro.
    Junot C; Theodoro F; Thierry J; Clement G; Wdzieczak-Bakala J; Ezan E
    J Immunoassay Immunochem; 2001; 22(1):15-31. PubMed ID: 11486817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effect of acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) analogs resistant to angiotensin I-converting enzyme on hematopoietic stem cell and progenitor cell proliferation.
    Gaudron S; Grillon C; Thierry J; Riches A; Wierenga PK; Wdzieczak-Bakala J
    Stem Cells; 1999; 17(2):100-6. PubMed ID: 10195570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline.
    Rieger KJ; Saez-Servent N; Papet MP; Wdzieczak-Bakala J; Morgat JL; Thierry J; Voelter W; Lenfant M
    Biochem J; 1993 Dec; 296 ( Pt 2)(Pt 2):373-8. PubMed ID: 8257427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.